Quantitative binding models for CYP2C9 based on benzbromarone analogues

被引:36
作者
Locuson, CW [1 ]
Rock, DA
Jones, JP
机构
[1] Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA
[2] Washington State Univ, Dept Chem, Pullman, WA 99164 USA
关键词
D O I
10.1021/bi049651o
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The cytochrome P450 (CYP) isoforms involved in xenobiotic metabolism are enzymes whose substrate selectivity remains difficult to predict due to wide specificity and dynamic protein-substrate interactions. To uncover the determinants of specificity for cytochrome CYP2C9, a novel library of benzbromarone (bzbr) inhibitors was used to reevaluate its pharmacophore. CoMSIA was used with the bzbr ligands to generate both quantitative binding models and three-dimensional contour plots that pinpoint predicted interactions that are important for binding to 2C9. Since this class of compounds is more potent than any other toward 2C9, the small molecule properties deemed most ideal by the software were used to address protein-ligand interactions using new mutagenesis and structural data. Nine new bzbr analogues provide evidence that specific electrostatic and hydrophobic interactions contribute the most to 2C9's specificity. Three of the new analogues are better isosteres of bzbr that contain bulky groups adjacent to the phenol and have increased pK(a) values. These ligands test the hypothesis that anionic substrates bind with higher affinity to 2C9. Since they have higher affinity than the previous nonacidic analogues, the importance of bulky groups on the phenol ring appears to have been underestimated. CoMSIA models predict that these bulky groups are favorable for their hydrophobicity, while a negative charge is favored at the ketone oxygen rather than the phenol oxygen. The overlap of this ketone with electronegative groups of other 2C9 substrates suggests they act as key positive charge acceptors.
引用
收藏
页码:6948 / 6958
页数:11
相关论文
共 37 条
[1]   Competitive CYP2C9 inhibitors:: Enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis [J].
Afzelius, L ;
Zamora, I ;
Ridderström, M ;
Andersson, TB ;
Karlén, A ;
Masimirembwa, CM .
MOLECULAR PHARMACOLOGY, 2001, 59 (04) :909-919
[2]   VANDERWAALS SURFACES IN MOLECULAR MODELING - IMPLEMENTATION WITH REAL-TIME COMPUTER-GRAPHICS [J].
BASH, PA ;
PATTABIRAMAN, N ;
HUANG, C ;
FERRIN, TE ;
LANGRIDGE, R .
SCIENCE, 1983, 222 (4630) :1325-1327
[3]   A SENSITIVE AND SPECIFIC STABLE ISOTOPE ASSAY FOR WARFARIN AND ITS METABOLITES [J].
BUSH, ED ;
LOW, LK ;
TRAGER, WF .
BIOMEDICAL MASS SPECTROMETRY, 1983, 10 (07) :395-398
[4]   COMPARATIVE MOLECULAR-FIELD ANALYSIS (COMFA) .1. EFFECT OF SHAPE ON BINDING OF STEROIDS TO CARRIER PROTEINS [J].
CRAMER, RD ;
PATTERSON, DE ;
BUNCE, JD .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1988, 110 (18) :5959-5967
[5]   METABOLISM OF BENZBROMARONE IN MAN - STRUCTURES OF NEW OXIDATIVE METABOLITES, 6-HYDROXY-BENZBROMARONE AND 1'-OXO-BENZBROMARONE, AND THE ENANTIOSELECTIVE FORMATION AND ELIMINATION OF 1'-HYDROXYBENZBROMARONE [J].
DEVRIES, JX ;
WALTERSACK, I ;
VOSS, A ;
FORSTER, W ;
PONS, PI ;
STOETZER, F ;
SPRAUL, M ;
ACKERMANN, M ;
MOYNA, G .
XENOBIOTICA, 1993, 23 (12) :1435-1450
[6]  
DICKMANN LJ, 2004, IN PRESS MOL PHARM
[7]  
Ekins S, 2000, DRUG METAB DISPOS, V28, P994
[8]  
Ekins S, 2001, DRUG METAB DISPOS, V29, P936
[9]  
ENGNELL AC, 2003, J PHARMACOL EXP THER, V307, P878
[10]   THE MIDAS DISPLAY SYSTEM [J].
FERRIN, TE ;
HUANG, CC ;
JARVIS, LE ;
LANGRIDGE, R .
JOURNAL OF MOLECULAR GRAPHICS, 1988, 6 (01) :13-&